Introduction

This page provides a comprehensive analysis of the known insider trading history of Fishman Corey N.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Fishman Corey N. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ITRM / Iterum Therapeutics plc Chief Executive Officer, Director 137,062
Director 0
Director 0
US:DRTX / Durata Therapeutics Inc CFO&COO 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Fishman Corey N.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Fishman Corey N. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-08-12 2024-08-06 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 82,613 137,062 151.73
2023-11-20 2023-11-20 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 10,000 54,449 22.50 1.59 15,863 86,372
2023-03-14 2023-03-11 4 ITRM Iterum Therapeutics plc
Ordinary Shares
F - Taxes -5,683 44,449 -11.34 0.96 -5,456 42,671
2023-03-14 2023-03-11 4 ITRM Iterum Therapeutics plc
Ordinary Shares
A - Award 14,333 50,132 40.04
2022-03-15 2022-03-11 4 ITRM Iterum Therapeutics plc
Restricted Share Units
M - Exercise -215,000 215,000 -50.00
2022-03-15 2022-03-11 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 215,000 537,008 66.77
2021-06-25 2021-06-23 4 ITRM Iterum Therapeutics plc
Stock Option (Right to Buy)
A - Award 5,280,000 5,280,000
2021-03-15 2021-03-11 4 ITRM Iterum Therapeutics plc
Restricted Share Units
A - Award 430,000 430,000
2021-01-27 2021-01-26 4 ITRM Iterum Therapeutics plc
Ordinary Shares
S - Sale -85,445 322,008 -20.97 1.73 -147,820 557,074
2021-01-27 2021-01-25 4 ITRM Iterum Therapeutics plc
Ordinary Shares
A - Award 167,500 407,453 69.81
2020-12-02 2020-12-02 4 BSTC BIOSPECIFICS TECHNOLOGIES CORP
Stock Option (Right to Buy)
D - Sale to Issuer -6,000 0 -100.00 32.87 -197,220
2020-12-02 2020-12-02 4 BSTC BIOSPECIFICS TECHNOLOGIES CORP
Common Stock, $0.001 par value
D - Sale to Issuer -2,018 0 -100.00
2020-05-04 2020-05-01 4 BSTC BIOSPECIFICS TECHNOLOGIES CORP
Stock Option (Right to Buy)
A - Award 6,000 6,000
2020-04-15 2020-04-13 4 BSTC BIOSPECIFICS TECHNOLOGIES CORP
Common Stock, $0.001 par value
A - Award 2,018 2,018
2019-06-21 2019-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Restricted Stock Unit
M - Exercise -4,356 0 -100.00
2019-06-21 2019-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Common Stock
M - Exercise 4,356 10,090 75.97
2019-06-21 2019-06-19 4 MNTA MOMENTA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 25,000 25,000
2019-02-19 2019-02-15 4 ITRM Iterum Therapeutics plc
Stock Option (Right to Buy)
A - Award 150,000 150,000
2018-08-21 2018-08-17 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 2,000 239,953 0.84 8.73 17,466 2,095,462
2018-06-25 2018-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -5,734 0 -100.00
2018-06-25 2018-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Restricted Stock Units
A - Award 4,356 4,356
2018-06-25 2018-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 8,855 8,855
2018-06-25 2018-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Common Stock
M - Exercise 5,734 5,734
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Series B-2 Preferred Shares
C - Conversion -1,591 0 -100.00
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Series B-1 Preferred Shares
C - Conversion -4,050 0 -100.00
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Series A Preferred Shares
C - Conversion -33,259 0 -100.00
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 3,000 237,953 1.28 13.00 39,000 3,093,389
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
C - Conversion 1,591 234,953 0.68
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
C - Conversion 4,050 233,362 1.77
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
C - Conversion 33,259 229,312 16.96
2018-05-29 2018-05-24 4 ITRM Iterum Therapeutics plc
Stock Option (Right to Buy)
A - Award 127,307 127,307
2018-05-24 3 ITRM Iterum Therapeutics plc
Ordinary Shares
392,106
2018-05-24 3 ITRM Iterum Therapeutics plc
Ordinary Shares
392,106
2018-05-24 3 ITRM Iterum Therapeutics plc
Ordinary Shares
392,106
2017-06-22 2017-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Restricted Stock Units
A - Award 5,734 5,734
2017-06-22 2017-06-20 4 MNTA MOMENTA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 11,207 11,207
2016-09-26 2016-09-22 4 MNTA MOMENTA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 33,000 33,000
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -110,000 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -50,000 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -12,500 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -21,574 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -218,750 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Common Stock
D - Sale to Issuer -24,941 0 -100.00
2014-05-22 2014-05-21 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
A - Award 110,000 412,824 36.32
2013-02-14 2013-02-12 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
A - Award 50,000 302,824 19.78 7.49 374,500 2,268,152
2012-07-26 2012-07-24 4 DRTX Durata Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -179,531 0 -100.00
2012-07-26 2012-07-24 4 DRTX Durata Therapeutics, Inc.
Common Stock
C - Conversion 22,441 22,441
2012-07-26 2012-03-15 4 DRTX Durata Therapeutics, Inc.
Series A Convertible Preferred Stock
P - Purchase 51,163 179,531 39.86 1.00 51,163 179,531
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)